2 of the best ASX 200 blue chip shares to buy now

MotleyFool
07-24

Looking to strengthen your portfolio with some blue chip ASX 200 shares?

If you are, then it could be worth checking out the two listed below that Bell Potter recently named as top picks on its Australian Equities Panel.

These are its favoured Australian equities that it believes offer attractive risk-adjusted returns over the long term.

Let's see what the broker is recommending to clients:

Flight Centre Travel Group Ltd (ASX: FLT)

The first ASX 200 blue chip share that could be a buy is Flight Centre.

It is a travel agent giant that operates under a number of well-known brands. This includes Flight Centre, Corporate Traveller, FCM, StudentUniverse, and Travel Associates.

Bell Potter believes that significant share price weakness this year has created a buying opportunity for investors. It highlights the low multiples its shares trade on and its strong earnings growth outlook as reasons to buy. It said:

 it effectively serves numerous market segments, covering everything from general leisure travel to specialised premium and youth services. With peak tariff uncertainty passed, we believe upside is not being priced into FLT. Trading at 10.8 12MF P/E and with an 18% EPS growth 2yr CAGR, there is potential for the stock to re-rate closer to its historical average. Continued costout initiatives and growth in corporate TTV help de-risk its cyclical nature, and with more potential RBA rate cuts, increased consumer spending on travel in FY26 could be a key beneficiary.

CSL Ltd (ASX: CSL)

Another ASX 200 blue chip share that Bell Potter is bullish on is biotechnology giant CSL.

This is another case of significant share price weakness creating a buying opportunity for investors. The broker highlights the discount its shares trade on compared to historical multiples. And this comes at a time when its growth outlook is the best it has been in years, with the broker forecasting strong earnings growth for the foreseeable future. It said:

CSL presents an attractive buying opportunity as we expect the margin recovery phase for CSL to drive above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~21x, representing a discount to its 10- year average of ~31x. Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10